Guangzhou, China, October 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (Nasdaq: POM) is a digital health company focused on advancing AI-powered medical solutions and predictive healthcare capabilities. The Company today announced that on October 6, 2026, it received a staff determination letter (the “Letter”) from the Nasdaq Stock Market LLC Listing Qualifications Department (“Staff”).
The company has been notified that the closing bid price of its American Depositary Shares (“ADSs”) was below $1.00 per share for 30 consecutive trading days from August 24, 2026, to October 5, 2026. As a result, the company has failed to comply with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (“Minimum Bid Price Requirement”).
Typically, Nasdaq-listed companies are granted 180 calendar days to regain compliance with the minimum bid price requirement. However, under Nasdaq Listing Rule 5810(c)(3)(A)(iv), the company is not eligible for any compliance period due to its 1-for-18 reverse stock split implemented on June 22, 2026, within the prior year.
Therefore, staff determined that the company’s securities will be delisted from the Nasdaq Global Market. Unless the company timely appeals to the Nasdaq Hearing Panel (the “Panel”), the company’s securities will be suspended from trading at the open on October 15, 2026, and Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission to remove the company’s securities from listing and registration on Nasdaq.
The company intends to timely request a hearing from the panel to appeal the staff’s determination and to submit a plan for regaining compliance with the minimum bid price requirement. The deadline for the company to request a hearing is October 13, 2026. If the hearing request is submitted on time, the suspension of trading in the company’s securities and the filing of Form 25-NSE will be stayed until the panel makes its decision. Therefore, no suspension of trading or delisting actions will be taken while the appeal is pending.
The company is evaluating alternative options to regain compliance with Nasdaq’s continued listing requirements. However, there is no guarantee that the staff will grant the company an extension to regain compliance, no guarantee that the company will be able to restore or maintain compliance with the minimum bid price requirement or any other Nasdaq continued listing requirement, and no guarantee that the company’s appeal will be successful.
About POMDOCTOR LIMITED
POMDOCTOR LIMITED (Nasdaq: POM) is a digital healthcare company focused on advancing AI-powered medical solutions and expanding predictive healthcare capabilities. The company leverages physician resources, wearable technology, artificial intelligence, healthcare payment networks, and real-world medical data to support more personalized, continuous, and data-driven healthcare services. For more information, visit the company’s website: http://ir.7shiliu.com.
Forward-looking statements
This press release contains forward-looking statements. These forward-looking statements include, but are not limited to: the company’s intention to request a hearing before the Panel, the anticipated effects of timely submitting a hearing request, the company’s appeal of the staff’s determination, the company’s plans and ability to regain and maintain compliance with Nasdaq’s continued listing requirements, the Panel’s review of the company’s appeal and compliance plan, and the continued listing of the company’s securities on Nasdaq.
Forward-looking statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied by such statements. Factors that could cause material differences in actual results include, but are not limited to: the panel’s decision on the company’s appeal, the company’s ability to regain and maintain compliance with the minimum bid price requirement and other Nasdaq continued listing requirements, fluctuations in the market price of the company’s ADSs, and other risks and uncertainties described in the company’s filings with the U.S. Securities and Exchange Commission.
Except as required by applicable law, the company has no obligation to update any forward-looking statements due to events or circumstances occurring after the date of this press release.
Investor Relations Contact
POMDOCTOR LIMITED
Investor Relations Department
Email: [email protected]
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]